PXVX0200 10E8 + PXVX0200 10E9 + Placebo + Shanchol
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cholera
Conditions
Cholera
Trial Timeline
Jul 1, 2014 → Mar 1, 2015
NCT ID
NCT02145377About PXVX0200 10E8 + PXVX0200 10E9 + Placebo + Shanchol
PXVX0200 10E8 + PXVX0200 10E9 + Placebo + Shanchol is a phase 2 stage product being developed by Emergent BioSolutions for Cholera. The current trial status is completed. This product is registered under clinical trial identifier NCT02145377. Target conditions include Cholera.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02145377 | Phase 2 | Completed |
Competing Products
9 competing products in Cholera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azithromycin | Pfizer | Phase 3 | 76 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Phase 3 | 76 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Approved | 84 |
| Ciprofloxacin | Bayer | Phase 3 | 74 |
| PXVX0200 + placebo | Bavarian Nordic | Phase 3 | 74 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 3 | 74 |
| VAXCHORA (Cholera Vaccine, Live, Oral) | Bavarian Nordic | Approved | 82 |
| PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo | Bavarian Nordic | Phase 3 | 74 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 1 | 30 |